Is anticoagulant therapy necessary after hospitalization with COVID-19 pneumonia?
https://doi.org/10.15829/1560-4071-2021-4652
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is associated with high virulence, mortality and healthcare burden around the world. One of its features is procoagulant activity, which leads to a high incidence of thromboembolic events in the lungs and other organs. Therefore, from the very onset of the moderate COVID-19, low molecular weight heparins began to be used as anticoagulants, which proved to have a beneficial effect on mortality and the disease course and were included in all guidelines. However, the question on anticoagulant therapy need after discharge from the hospital is controversial. The opinions of various medical professional communities on this issue are divided. In particular, some of them, including the Russian Ministry of Health guidelines recommend 30-45day anticoagulation using novel oral anticoagulants (dabigatran, rivaroxaban, apixaban), but other sources do not provide such recommendations. This review discusses the effectiveness of anticoagulant therapy after COVID-19, as well as the need to use stratification scales to assess this therapy.
About the Authors
P. A. Davtyan
Bashkir State Medical University
Russian Federation
Competing Interests:
Russian Federation
Ufa.
Competing Interests:
None
R. M. Gumerov
Bashkir State Medical University
Russian Federation
Competing Interests:
Russian Federation
Ufa.
Competing Interests:
None
Sh. Z. Zagidullin
Bashkir State Medical University
Russian Federation
Competing Interests:
Russian Federation
Ufa.
Competing Interests:
None
A. V. Samorodov
Bashkir State Medical University
Russian Federation
Competing Interests:
Russian Federation
Ufa.
Competing Interests:
None
B. Cai
Harbin Medical University
China
Competing Interests:
China
Harbin.
Competing Interests:
None
N. Sh. Zagidullin
Bashkir State Medical University
Russian Federation
Competing Interests:
Russian Federation
Ufa.
Competing Interests:
None
References
1. Mehta P, McAuley DF, Brown M, et al., Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229): 1033-4. doi:10.1016/S0140-6736(20)30628-0.
2. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and com- plications of COVID-19. Am J Hematol. 2020;95(07):834-47. doi:10.1002/ajh.25829.
3. Maglakelidze N, Manto KM, Craig TJA. A review: does complement or the contact system have a role in protection or pathogenesis of COVID-19? Pulm Ther. 2020;6(02):169-76. doi:10.1007/s41030-020-00118-5.
4. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J. Am. Coll. Cardiol. 2020;75(23):2950-73. doi:10.1016/j.jacc.2020.04.031.
5. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-7. doi:10.1016/j.thromres.2020.04.013.
6. Hanif A, Khan S, Mantri N, et al. Thrombotic complications and anticoagulation in COVID-19 pneumonia: a New York City hospital experience. Ann. Hematol. 2020;99(10):2323-8. doi:10.1007/s00277-020-04216-x.
7. Spyropoulos AC, Weitz JI. Hospitalized COVID-19 patients and venous thromboembolism. Circulation. 2020;142(2):129-32. doi:10.1161/CIRCULATIONAHA.120.048020.
8. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020;41(19):1858. doi:10.1093/eurheartj/ehaa254.
9. Spyropoulos AC, Lipardi C, Xu J, et al. Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis. TH Open Companion J. Thromb. Haemost. 2020;4(1):e59-e65. doi:10.1055/s-0040-1705137.
10. Gerotziafas GT, Catalano M, Theodorou Y, et al.; Scientific Reviewer Committee. The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. Thromb Haemost. 2021;121(8):992-1007. doi:10.1055/a-1535-8807.
11. American Society of Hematology. ASH Guidelines on Use of Anticoagulation in Patients with COVID-19. 2020; https://www.hematology.org/education/clinicians/guidelines-and-quality%20care/clinical-practice-guidelines/venous-thromboembolism-guidelines/ash%20guidelines-on-use-of-anticoagulation-in-patients-with-covid-19. Accessed December 15,2020.
12. National Institutes of Health. Antithrombotic therapy in patients with COVID-19. Updated May 12, 2020. https://www.covid19treatmentguidelines.nih.gov/adjunctivetherapy/antithrombotic-therapy/.
13. Recommendations of the Ministry of Health on the treatment of coronavirus. Version No. 13 (14.10.2021). (In Russ.) https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/211/original/BMP-13.pdf.
14. Lombardo MDM, Foppiani A, Peretti GM, et al. Long-Term Coronavirus Disease 2019 Complications in Inpatients and Outpatients: A One-Year Follow-up Cohort Study. Open Forum Infect Dis. 2021;16:8(8):ofab384. doi:10.1093/ofid/ofab384.
15. Cohoon KP, Mahé G, Tafur AJ, Spyropoulos AC. Emergence of Institutional Antithrom- botic Protocols for Coronavirus 2019. Res. Pract. Thromb. Haemost. 2020;4(4):510-7. doi:10.1002/rth2.12358.
16. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, Diagnosis, and Treatment of VTE in Patients With COVID-19. Chest. 2020;158(3):1143-63. doi:10.1016/j.chest.2020.05.559.
17. Anderson DR, Morgano GP, Bennett C, et al. 2019 ASH surgical prophylaxis guideline. Blood Adv. 2019;3(23):3898-944. doi:10.1182/bloodadvances.2019000975.
18. Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198-225. doi:10.1182/bloodadvances.2018022954.
19. NICE guideline: COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT). https://www.nice.org.uk/guidance/ng89.
20. Pons S, Fodil S, Azoulay E, Zafrani L. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care. 2020;24(01):353. doi:10.1186/s13054-020-03062-7.
21. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-8. doi:10.1016/S0140-6736(20)30937-5.
22. Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(02):631-7. doi:10.1002/path.1570
23. Aimes RT, Zijlstra A, Hooper JD, et al. Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb Haemost. 2003;89(03):561-72.
24. Zagidullin NS, Gareeva DF, Ishmetov VS, et al. Renin-angiotensin-aldosterone system in new coronavirus infection 2019. “Arterial’naya Gipertenziya” (“Arterial Hypertension”). 2020;26(3):240-7. (In Russ.) doi:10.18705/1607-419X-2020-26-3-240-247.
25. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-74. doi:10.1016/S0140-6736(20)30251-8.
26. Fogarty H, Townsend L, Ni Cheallaigh C, et al. More on COVID-19 coagulopathy in Caucasian patients. Br J Haematol. 2020;189(06):1060-1. doi:10.1111/bjh.16791.
27. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844-7. doi:10.1111/jth.14768.
28. Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18:1738-42. doi:10.1111/jth.14850.
29. Helms J, Tacquard C, Severac F, et al.; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-98. doi:10.1007/s00134-020-06062-x.
30. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-4. doi:10.1111/jth.14830.
31. Llitjos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;18(7):1743-6. doi:10.1111/jth.14869.
32. Nahum J, Morichau-Beauchant T, Daviaud F, et al. Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19). JAMA Netw Open. 2020;3(5):e2010478. doi:10.1001/jamanetworkopen.2020.10478.
33. Lodigiani C, Iapichino G, Carenzo L, et al.; Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14. doi:10.1016/j.thromres.2020.04.024.
34. Biembengut ÍV, de Souza TACB. Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach. Mem Inst Oswaldo Cruz. 2020;115:e200179. doi:10.1590/0074-02760200179.
35. Eleftheriou P, Amanatidou D, Petrou A, Geronikaki A. In silico evaluation of the effectivity of approved protease inhibitors against the main protease of the novel SARS-CoV-2 virus. Molecules. 2020;25(11):E2529. doi:10.3390/molecules25112529.
36. Marietta M, Ageno W, Artoni A, et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus. 2020;18(3):167-9. doi:10.2450/2020.0083-20.
37. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259-64. doi:10.1038/s41586-021-03553-9.
38. Patell R, Bogue T, Koshy A, et al. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020;10:136(11):1342-6. doi:10.1182/blood.2020007938.
39. Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in patients with COVID-19: Awareness of an increased prevalence. Circulation. 2020;142(2):184-6. doi:10.1161/CIRCULATIONAHA.120.047430.
40. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19). Updated February 12, 2021. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care.html.
41. Giannis D, Allen SL, Tsang J, et al. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood. 2021;20;137(20):2838-47. doi:10.1182/blood.2020010529.
42. Lax SF, Skok K, Zechner P, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: Results from a prospective, single-center, clinicopathologic case series. Ann. Intern. Med. 2020;173:350-61. doi:10.7326/M20-2566.
43. Wichmann D, Sperhake J-P, Lütgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: A Prospective Cohort Study. Ann. Intern. Med. 2020;173(4):268-77. doi:10.7326/L20-1206.
44. Roberts LN, Whyte MB, Georgiou L, et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood. 2020;136(11):1347-50. doi:10.1182/blood.2020008086.
45. Gibson CM, Korjian S, Chi G, et al. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. J. Am. Heart Assoc. 2017;6(7):e006015. doi:10.1161/JAHA.117.006015.
46. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrom- botic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e195S-e226S. doi:10.1378/chest.11-2296.
47. Chiasakul T, Evans CR, Spyropoulos AC, et al. Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis. Thromb Res. 2019;184:58-61. doi:10.1016/j.thromres.2019.10.027.
48. Cohen AT, Harrington RA, Goldhaber SZ, et al.; APEX Investigators. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med. 2016;375(6):534-44. doi:10.1056/NEJMoa1601747.
49. Cohen AT, Spiro TE, Spyropoulos AC; MAGELLAN Steering Committee. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(20):1945-6. doi:10.1056/NEJMc1303641.
Supplementary files
Review
For citations:
Davtyan P.A., Gumerov R.M., Zagidullin Sh.Z., Samorodov A.V., Cai B., Zagidullin N.Sh. Is anticoagulant therapy necessary after hospitalization with COVID-19 pneumonia? Russian Journal of Cardiology. 2021;26(4S):4652. (In Russ.) https://doi.org/10.15829/1560-4071-2021-4652
Views:
4787
Email this article 